Fibroblast growth factor receptor 3 overexpression mediates <scp>ALK</scp> inhibitor resistance in <scp>ALK</scp> ‐rearranged non–small cell lung cancer-Reference-Cited by-同舟云学术

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK ‐rearranged non–small cell lung cancer

Published:2022-09-11 Issue:11 Volume:113 Page:3888-3900
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Sakashita Takuya¹²³,Yanagitani Noriko⁴,Koike Sumie¹,Low Siew‐Kee⁵^ORCID,Takagi Satoshi¹,Baba Satoko⁶⁷,Takeuchi Kengo⁶⁷⁸,Nishio Makoto⁴^ORCID,Fujita Naoya⁹^ORCID,Katayama Ryohei¹²^ORCID

Affiliation:

1. Division of Experimental Chemotherapy, Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan

2. Department of Computational Biology and Medical Science, Graduate School of Frontier Sciences The University of Tokyo Tokyo Japan

3. Science Enablement Department Science & Data Analytics Division, Research & Development AstraZeneca K.K Osaka Japan

4. Department of Thoracic Medical Oncology, The Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan

5. Cancer Precision Medicine Center The Cancer Institute, Japanese Foundation for Cancer Research Tokyo Japan

6. Division of Pathology, Cancer Institute Japanese Foundation for Cancer Research Tokyo Japan

7. Pathology Project for Molecular Targets the Cancer Institute, Japanese Foundation for Cancer Research Tokyo Japan

8. Department of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan

9. Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan

Funder

Japan Agency for Medical Research and Development

Japan Society for the Promotion of Science

Nippon Foundation

Princess Takamatsu Cancer Research Fund

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15529

Reference55 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

3. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer;Cancer Letters;2024-11

2. Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer;Cancer Letters;2024-04

3. Regulatory mechanism of the Glabrene against non‐small cell lung cancer by suppressing FGFR3;Environmental Toxicology;2024-03-22

4. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy;Biochemical and Biophysical Research Communications;2023-12

5. Study on the Improvement of Immune Microenvironment in Lung Cancer by the Combination of Three-Step Analgesics and Glabrene Based on Network Pharmacology and Molecular Docking Analysis;J BIOL REG HOMEOS AG;2023